Skip to content

REsearching Covid-19 Outcomes in Diabetes (RECODE)

REsearching Covid-19 Outcomes in Diabetes (RECODE)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04805970
Acronym
RECODE
Enrollment
35
Registered
2021-03-18
Start date
2021-03-24
Completion date
2026-12-01
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, Diabetes

Brief summary

The purpose of this study is to observe any changes that may occur to certain organs following a confirmed diagnosis of COVID-19 in people with and without diabetes.

Interventions

None listed

Sponsors

AdventHealth Translational Research Institute
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

For Type 2 Diabetes (T2D) 1. Male or female 18 years of age and older willing and able to give informed consent to participate in the study 2. Confirmed diagnosis of SARS-CoV-2 RNA via a polymerase chain reaction (PCR) assay (having been discharged at least 2 months from hospital but not greater than 6 months). 3. Diagnosis of T2D according to American Diabetes Association (ADA) criteria. 4. Must have access to a computer/laptop or a modern (no more than 3-4 years old) smart phone/tablet for cognitive assessments. For participant without Type 2 Diabetes (T2D) 1. Male or female 18 years of age and older willing and able to give informed consent to participate in the study 2. Confirmed diagnosis of SARS-CoV-2 RNA via a polymerase chain reaction (PCR) assay (having been discharged at least 2 months from hospital but not greater than 6 months). 3. Must have access to a computer/laptop or a modern (no more than 3-4 years old) smart phone/tablet for cognitive assessments.

Exclusion criteria

1. Symptoms of active respiratory viral infection: 1. high temperature (over 37.8°C/100.4°F) 2. cough (consistent for over an hour; 3 or more episodes in 24 hours) 2. Any history of Type I diabetes 3. The participant may not enter the study with any known contraindication to magnetic resonance imaging including 1. Pregnancy, lactation or 6 months postpartum from the scheduled date of collection 2. Metal implants (pacemaker, aneurysm clips) based on Investigator's judgment at Screening 3. Unable to participate in MRI assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on Investigator's judgment at Screening 4. Unable to tolerate MRI imaging or claustrophobia 4. Any condition, including a significant underlying disease or disorder which, in the opinion of the investigator, may put the participant at risk by participating in the study or limit the participant's ability to participate.

Design outcomes

Primary

MeasureTime frameDescription
Measure and characterize organ volume change in patients with and without diabetes through use of summary statistics.1 yearPatients recovering from the COVID-19 disease

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRichard Pratley, MD

AdventHealth Orlando

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026